The Hbsag/hbv Dna Ratio's Potential For Predicting Disease Progression

Patients pinch chronic hepatitis B microorganism (HBV) infection successful nan immune-tolerant shape whitethorn still acquisition hepatic inflammation and illness progression, and could use from early antiviral treatment.

This study aimed to analyse changes successful nan cumulative hepatitis B aboveground antigen (HBsAg)/HBV DNA ratio successful immune-tolerant patients during nan modulation to nan immune-active phase, and to measure its imaginable successful predicting nan consequence of illness progression.

Methods

This longitudinal study included 127 untreated immune-tolerant patients, who were followed for up to 10 years. An independent cohort of 109 subjects was retrospectively enrolled for outer validation. The narration betwixt nan cumulative HBsAg/HBV DNA ratio and nan long of immune tolerance aliases modulation to nan immune-active shape was examined. The predictive worth of nan ratio was assessed and validated.

Results

The narration betwixt nan cumulative HBsAg/HBV DNA ratio and illness progression consequence showed a non-linear pattern: beneath a ratio of 1.791, nan consequence of illness progression decreased quickly arsenic nan ratio increased; supra 1.791, nan consequence plateaued. The area nether nan curve for predicting illness progression was 0.67, 0.64, and 0.85 for cumulative HBsAg, HBV DNA, and nan HBsAg/HBV DNA ratio, respectively.

Multivariable Cox regression study revealed nan cumulative HBsAg/HBV DNA ratio arsenic an independent predictor of illness progression, pinch higher ratios associated pinch a little risk. Prediction models incorporating this ratio were developed and externally validated, demonstrating beardown capacity and objective utility.

Conclusions

This study identifies nan cumulative HBsAg/HBV DNA ratio arsenic an independent predictor of immune tolerance long successful patients pinch chronic HBV infection. A little ratio correlates pinch an accrued consequence of modulation from nan immune-tolerant shape to nan immune-active phase, peculiarly erstwhile it falls beneath 1.791, astatine which constituent nan consequence of illness progression increases sharply.

Additionally, patients aged ≥30 years look a notably higher consequence of illness progression, underscoring nan request for vigilant monitoring successful this population. These findings person important implications for nan proactive guidance of immune-tolerant patients. Early discovery of illness progression and timely antiviral curen whitethorn yet amended objective outcomes and societal benefits for individuals suffering from chronic HBV infection.